GSK plc (LON:GSK - Get Free Report) insider Emma Walmsley sold 120,653 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.29), for a total value of £1,753,088.09 ($2,206,530.01).
GSK Stock Performance
Shares of LON:GSK traded down GBX 9.50 ($0.12) on Friday, reaching GBX 1,435 ($18.06). 5,979,453 shares of the company's stock were exchanged, compared to its average volume of 26,154,219. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The company has a market capitalization of £58.23 billion, a price-to-earnings ratio of 23.18, a PEG ratio of 1.24 and a beta of 0.31. The company has a fifty day moving average of GBX 1,369.25 and a 200-day moving average of GBX 1,454.36. GSK plc has a twelve month low of GBX 1,282.50 ($16.14) and a twelve month high of GBX 1,823.50 ($22.95).
GSK (LON:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, research analysts predict that GSK plc will post 175.980975 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the stock. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank lowered their target price on GSK from GBX 1,820 ($22.91) to GBX 1,600 ($20.14) and set a "buy" rating on the stock in a research note on Friday, November 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of GBX 1,805.83 ($22.73).
Get Our Latest Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
